A study of effect of the first treatment choice (laser photocoagulation (LPC) or intravitreal ranibizumab (IVR)) on the prognosis of stage 4A retinopathy of prematurity

Trial Profile

A study of effect of the first treatment choice (laser photocoagulation (LPC) or intravitreal ranibizumab (IVR)) on the prognosis of stage 4A retinopathy of prematurity

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinopathy of prematurity
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top